Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Amgen Inc. pages available for free this week:
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Amgen Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
An examination of the investment activity ratios reveals distinct trends over the observed period. The net fixed asset turnover demonstrates relative stability with an increasing trend in the latter half of the period, while total asset turnover exhibits a more pronounced, albeit gradual, increase. Equity turnover displays significant volatility followed by a stabilizing pattern.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio began at 4.75 and fluctuated around the 4.5 to 4.8 range through the end of 2023. A clear upward trend emerges in 2024, peaking at 5.06 before settling around 4.91 by the end of the first quarter of 2025. A slight decline is then observed, concluding at 4.44. This suggests increasing efficiency in utilizing fixed assets to generate revenue, particularly in 2024, followed by a potential shift in asset utilization strategy or operational changes.
- Total Asset Turnover
- The total asset turnover ratio remained relatively consistent at approximately 0.41 in the first half of the period. A substantial decrease is noted starting in the first quarter of 2023, falling to 0.28 and remaining at that level for three consecutive quarters. A gradual recovery begins in the first quarter of 2024, steadily increasing to 0.39 by the end of 2025. This pattern indicates a period of reduced efficiency in asset utilization, followed by a progressive improvement in how effectively assets are employed to generate sales.
- Equity Turnover
- The equity turnover ratio experienced considerable fluctuation. It began at a high of 26.68, then decreased sharply to 6.71 by September 2022. A moderate recovery occurred through the end of 2023, reaching 4.32. The ratio then increased to 5.45 in late 2024 before decreasing to 4.06 by the end of 2025. This volatility suggests significant changes in the relationship between revenue and equity, potentially due to shifts in capital structure, profitability, or asset deployment strategies. The ratio appears to stabilize in the 4.0 to 5.5 range in the latter part of the observed period.
Overall, the observed trends suggest a dynamic period for the company. While fixed asset utilization improved in the later quarters, the initial decline and subsequent recovery in total asset turnover warrant further investigation. The equity turnover ratio’s volatility highlights the need to monitor capital management and its impact on revenue generation.
Net Fixed Asset Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Product sales | |||||||||||||||||||||
| Property, plant and equipment, net | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Net fixed asset turnover
= (Product salesQ4 2025
+ Product salesQ3 2025
+ Product salesQ2 2025
+ Product salesQ1 2025)
÷ Property, plant and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The net fixed asset turnover ratio for the analyzed period demonstrates a generally stable performance with some fluctuations. Initially, the ratio exhibited a slight increase from 4.75 in March 2022 to 4.77 in June 2022, followed by a minor decrease to 4.73 in September 2022 and a more noticeable decline to 4.57 by December 2022.
A period of relative stability followed in the first half of 2023, with the ratio fluctuating between 4.56 and 4.58. However, a significant increase is observed in the latter half of 2023, peaking at 5.06 in September 2023 before settling at 4.89 in December 2023. This upward trend continued into the first half of 2024, reaching 4.85 in June 2024 and 4.70 in March 2024.
The ratio continued to increase through the end of 2024, reaching 5.06 in September 2024 and 4.89 in December 2024. A slight decrease is observed in the first half of 2025, with the ratio falling to 4.91 in March 2025 and 4.89 in June 2025. The ratio then decreased to 4.78 in September 2025 and further to 4.44 in December 2025.
- Overall Trend
- The net fixed asset turnover ratio generally remained within a narrow band between 4.44 and 5.06 throughout the analyzed period. While fluctuations occurred, a clear, sustained upward or downward trend is not evident. The most significant change is the decrease observed in December 2025.
- Peak Performance
- The highest ratio value of 5.06 was recorded in September 2023 and again in September 2024, indicating the most efficient utilization of fixed assets to generate product sales during those quarters.
- Lowest Performance
- The lowest ratio value of 4.44 was recorded in December 2025, suggesting a less efficient utilization of fixed assets during that quarter. This warrants further investigation to understand the underlying causes.
- Recent Developments
- The decline in the ratio during December 2025 represents a recent shift in performance. This decrease, following a period of relative stability and growth, could indicate emerging challenges in asset utilization or a change in sales patterns.
Total Asset Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Product sales | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Total asset turnover
= (Product salesQ4 2025
+ Product salesQ3 2025
+ Product salesQ2 2025
+ Product salesQ1 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio for the analyzed period demonstrates a generally low and initially stable trend, followed by a modest improvement. The ratio reflects the efficiency with which assets are utilized to generate product sales. Initial values are observed around 0.41, then decline and subsequently show a gradual increase.
- Initial Stability and Decline (Mar 31, 2022 – Dec 31, 2022)
- From March 31, 2022, through December 31, 2022, the total asset turnover ratio remained consistently at 0.41 and then decreased to 0.38. This indicates that for every dollar of assets, the company generated approximately 41 to 38 cents in product sales. The slight decline suggests a decreasing efficiency in asset utilization during this period.
- Period of Low Turnover (Mar 31, 2023 – Dec 31, 2023)
- The ratio remained stable at 0.28 from March 31, 2023, to December 31, 2023. This represents a significant decrease from the prior period, indicating a substantial reduction in sales generated per dollar of assets. This could be attributed to an increase in total assets without a corresponding increase in product sales.
- Gradual Improvement (Mar 31, 2024 – Dec 31, 2025)
- Beginning March 31, 2024, the total asset turnover ratio began a gradual upward trend, increasing from 0.30 to 0.39 by December 31, 2025. This suggests an improving efficiency in asset utilization, with the company generating more sales relative to its asset base. The increase, while positive, remains modest, and the ratio remains below the initial levels observed in 2022.
Overall, the observed pattern suggests a period of declining asset utilization followed by a slow recovery. The increase in the ratio towards the end of the analyzed period is a positive sign, but continued monitoring is warranted to assess whether this trend will continue and reach levels comparable to those seen earlier in the period.
Equity Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Product sales | |||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Equity turnover
= (Product salesQ4 2025
+ Product salesQ3 2025
+ Product salesQ2 2025
+ Product salesQ1 2025)
÷ Stockholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The equity turnover ratio exhibits considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrates a substantial decline from 26.68 to 6.71, followed by a period of relative stability and then renewed volatility. A general observation suggests a decreasing trend over the entire timeframe, although punctuated by intermittent increases.
- Initial Decline (Mar 31, 2022 – Sep 30, 2022)
- A significant decrease in the equity turnover ratio is apparent during this period. Starting at 26.68, the ratio falls to 10.17, then continues downward to 6.71. This suggests a diminishing ability to generate product sales relative to the level of stockholders’ equity. The most substantial drop occurs between March and June 2022.
- Stabilization and Moderate Increase (Dec 31, 2022 – Mar 31, 2024)
- Following the initial decline, the ratio stabilizes somewhat, fluctuating between 3.35 and 6.77. A moderate increase is observed from December 2022 (4.32) to March 2024 (5.61), indicating a slight improvement in sales generation relative to equity. However, this improvement is not sustained.
- Recent Volatility (Jun 30, 2024 – Dec 31, 2025)
- The latter portion of the period is characterized by increased volatility. The ratio moves from 4.99 to 5.45, then decreases to 4.51, increases to 3.59, and finally rises to 4.06. This suggests inconsistent performance in utilizing equity to generate product sales. The final value, 4.06, is considerably lower than the initial value of 26.68, indicating a long-term downward trend.
The fluctuations in the equity turnover ratio may be attributable to changes in product sales, stockholders’ equity, or a combination of both. Further investigation into the underlying drivers of these changes is recommended to understand the company’s operational efficiency and financial performance.